First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended ...

For the first time, NICE has recommended a targeted treatment option for ALK-positive non-small-cell lung cancer, to be given after surgery to reduce the risk of the disease coming back. NICE ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

All NICE products on oesophageal cancer. Includes any guidance and quality standards.

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

The new modifier was introduced in 2022 to allow extra weight to be given to medicines that address severe diseases. It ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.